65,437 trials
Malignant Neoplasm
Primary: Complete Response (CR) Defined as no Emesis and no Rescue Therapy — 13 Participants
Primary Progressive Aphasia
Primary: Aphasia Severity (WAB-AQ): Effects of Active tDCS (Baseline vs. 0 Weeks Immediately Following Stimulation) — 2.68; .87; 1.98; 2.25 score on a scale — p=0.14
Healthy · Healthy Volunteers
Primary: Ad Libitum Energy Intake — 2752; 2063 kcal per day
Ovarian Cancer
Primary: Progression-free Survival (PFS) at 6 Months — 58.6 percentage of participants
Pharmacogenetics
Primary: Number of Patient Participants' Acceptance of PGx Services Offered in Community Pharmacy Setting — 14; 13 Participants
Alcohol Use Disorder
Primary: Alcohol Consumption in Alcohol Self-Administration Trials — 3.02; 2.35 Standard Drink Units (SDU)
Mucositis
Primary: Mucositis — 0.37; 2.84; 0.34; 2.87 score on a scale
Heart Arrhythmia
Primary: Logistics of Study Device Setup and Monitoring — 51; 51; 51; 51 count of participants
Advanced Parkinson's Disease
Primary: Change From Baseline to Week 26 in the NMSS Total Score — -23.83; -32.04 score on a scale — p=0.410
Dysphonia Resulting From Vocal Fold Scarring · Age-related Dysphonia
Primary: Number of Participants With Any Improvement From Baseline in Mucosal Wave Grade — 14; 5 Participants
Classical Hodgkin's Lymphoma
Primary: Objective Response Rate (ORR) as Assessed by the Investigator Based on Cheson Response Criteria — 5; 30; 71; 14 Participants
Healthy Volunteers
Primary: Peak Plasma Concentration (Cmax) of Sertraline — 28.3; 28.8 ng/mL
Diabetes Mellitus, Type 2
Primary: Hemoglobin A1c at 6 Months — -1.32; -2.85 percentage of DCCT units
Recurrent Glioblastoma
Primary: Progression-free-survival — 20; 16 percentage of participants
Cancer
Primary: Number of Participants Who Experience Dose Limiting Toxicity (DLT) During NOX66 Monotherapy and During NOX66 Combination With Carboplatin — 0; 0; 0; 0 Participants